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Research Questions: 
1. Do antiretroviral treatment programs for the treatment ofHIV -infection 
reduce AIDS-related mortality and improve immunovirologic markers in 
HIV-infected adults in Haiti and the countries of sub-Saharan Africa? 
2. What factors contribute to the improvement of health outcomes in 
antiretroviral treatment programs for HIV-infected individuals in sub-
Saharan Africa and Haiti? 
"Don't believe it when they tell me there ain't no cure 
The rich stay healthy and the sick stay poor" 
--U2 
Background 
Burden of suffering 
Human immunodeficiency virus (HIV), the infectious agent of acquired 
immune deficiency syndrome (AIDS), currently infects forty million people 
throughout the world, and in 2000, surpassed TB to kill more people each year 
than does any other infectious agent. 1' 2 Three million individuals died of 
HIV/AIDS in 2003, and ninety percent of those deaths occurred among people 
living in the world's poorest countries where few if any resources exist to combat 
the disease3 Furthermore, in 2003, an estimated five million individuals were 
newly infected with HIV. 4 
1 
Though the pandemic spans the globe, it disproportionately infects, 
affects, and entrenches itself in the populations of the poorest regions on the 
planet. Seventy percent of the world's infected individuals live in sub-Saharan 
Africa alone, where HIV infects an estimated twenty-seven million adults and 
children-more infected individuals than in all the other countries of the world 
combined.3 Sub-Saharan Africa has the highest adult HN -prevalence of any 
region in the world at eight percent, with HN infecting over thirty percent of the 
adult populations of Botswana, Lesotho, Swaziland, and Zimbabwe.5 In the 
Caribbean, the world's second hardest hit region, HN infects 2.2 percent of the 
adult population, and in Haiti, the poorest cmmtry in the Caribbean and the 
Western hemisphere, adult HN prevalence estimates range from 5.5 to 6.1 %4 • 5 
Not only does HIV/AIDS inflict a significant amount of morbidity and 
mortality, the disease exerts a tremendous economic, social, and political burden 
upon resource-poor countries. The HIV I AIDS pandemic threatens to destroy the 
societies, economies, infrastructures, and national and regional security of many 
nations.6 Acquired immune deficiency syndrome-related deaths disrupt family 
structures and seriously reduce entire work forces including those of agricultural 
workers, health professionals, and teachers7 -10 Of the fourteen million children 
orphaned by the AIDS-related death of their parents, eleven million live in sub-
Saharan Africa5 Human immunodeficiency virus infection acts synergistically 
with other diseases to overwhelm the already inadequate and overburdened 
medical facilities in developing countries.8' 11 ' 12 The stigma associated with 
HN/AIDS constitutes an additional socio-cultural burden to be born by infected 
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individuals and their families. Many HIV-infected individuals report abuse by 
family and neighbors. 
Disparities in access to antiretroviral medications between wealthy and poor 
countries 
In the U.S. and Europe, HN infects and kills only a fraction of the munber 
it does in poorer nations.4 The U.S. and other industrialized Western countries 
thus might be said to be "resistant" to HIV I AIDS and better equipped to defend 
themselves against the virus once infected. The effectiveness of antiretroviral 
therapy (ART) for the treatment ofHN/AIDS in the industrialized world is well-
established. 13-15 The introduction of highly active antiretroviral therapy 
(HAART) in 1997 sharply decreased AIDS-related mortality, morbidity, and 
hospitalizations in wealthier industrialized countries. While HAART has become 
the standard of care for HIV -infected patients in wealthier nations, international 
health experts have traditionally considered ART to be unfeasible in developing 
countries. 16• 17 Haiti and the countries of sub-Saharan Africa represent, by almost 
any standard, the poorest areas of the world. 18 
According to the World Health Organization (WHO), six million people 
living in the world's poorest countries are in desperate need of antiretroviral 
(ARV) medications, though only 300,000 of those in need currently receive 
them. 19 Despite widespread use in wealthy nations, ART in developing countries 
remains a novel concept, first entertained seriously only in 1998 at the 12'h World 
AIDS conference in Geneva. As a result, we know little about the use of 
antiretroviral therapy in developing countries, especially those in sub-Saharan 
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Africa and Haiti. The inequitable distribution of antiretroviral medications 
persists and perpetuates the disparate dichotomy that exists between wealthy and 
poor nations. 
Prevention efforts not sufficient 
Current international HIV I AIDS strategies in developing countries focus 
primarily on preventing HIV infection rather than preventing the progression of 
HIV disease in those already infected. The annually increasing numbers of 
newly infected individuals suggests this approach is inadequate. 
A whole consists not of the sum of its parts.20• 21 Many infectious disease 
experts argue that health workers and officials need to link prevention efforts with 
care, including the provision of antiretroviral therapy to those already infected 
with HIV. 1• 6• 8• 22 Preventive and curative medicine likely act synergistically to 
produce better health outcomes. 
The medical anthropologist George Foster in 1952 found that people in 
resource-poor countries are interested in prevention only after their first priority, 
treatment of illness, is satisfied23 Some HIV/AIDS activists in many sub-Saharan 
African countries are becoming increasingly hostile toward international health 
agencies that provide only prevention without treatment for those already infected 
with HIV. 1 They want HIV medications for those who have AIDS, not just 
condoms and prevention messages for those not yet infected. 
Treatment may also decrease transmission by reducing viral load, as a 
high viral load is associated with increased HIV infectiousness24' 26 Managing 
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HN disease with treatment may therefore constitute a means of secondary 
prevention that is not well emphasized in developing countries. 
Obstacles to providing antiretrovirals in resource-poor settings 
Objection to providing ART in developing countries centers around the 
following obstacles: the high cost of medications relative to national health 
budgets in resource-poor settings, lack of health infrastructure to provide 
treatment and follow-up, concerns about possible lack of adherence to treatment, 
the risk of perpetuating inequalities between the rich and poor, and the emergence 
of viral resistance27 
Recent sharp drops in the price of ART medications, however, now render 
ART increasingly practical, at least on financial grounds. Generic manufacturers 
in India, China, and other countries now produce and sell antiretroviral 
medications at substantially lower prices. The availability of inexpensive 
medications, however, will likely affect only the few in resource-poor settings 
who have regular access to medical services. 6 
If faced with the extremely high HN prevalence of poorer countries, 
many wealthier nations might also experience the disintegrations of their public 
health services, as well. Some estimate that for every one dollar spent for 
antiretroviral medications, three dollars are necessary for health infrastmcture. 
Inexpensive antiretroviral regimens to decrease vertical transmission of HIV are 
still not available to many in Africa, despite their cheap price, because of the lack 
of health care infrastructure and the presence of political complacency.6 
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Managing HIV infection requires not only access to ART medications, but 
adherence to potentially complicated dosing regimens, as well. Farmer, et. a/.8 
point to tuberculosis (TB) as an example of a chronic infection well-managed in 
resource-poor settings. Like HIV/AIDS, multi-drug resistant TB (MDR-TB) is 
managed with multiple medications on a long-term basis. The success of 
managing TB with the provision of directly observed treatment (DOT) by health 
workers or trained community members may serve as a model for HIV treatment 
with ART in sub-Saharan Africa and other parts of Haiti. 
Can ART interventions work in Haiti and sub-Saharan Africa? 
A number of unanswered questions exist regarding the establishment and 
expansion of ART programs in resource-poor countries such as sub-Saharan 
Africa and Haiti: 
• Do these countries have the capacity to establish and maintain programs to 
treat large numbers ofHIV-infected patients? 
• In successful ART programs, what factors contribute to improved health 
outcomes for HIV -positive individuals in these countries? 
• As interest in providing ARV therapy increases in developing countries, 
what should new programs look like to effectively provide ARV therapy? 
This paper is a systematic review of existing programs that provide ART 
in sub-Saharan Africa and Haiti. It proposes to report the health outcomes of 
ART provision in those areas and to identify factors that contribute to the failures 
and successes of those programs. Primary health outcomes used to assess 
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program effectiveness include AIDS-related mortality and the surrogate 
immunovirologic markers of CD4+ cell count and viral load. Findings from this 
study will be useful to ascertain the effectiveness of ART programs in developing 
countries, and to determine if programs are successful enough to warrant a shift in 
international health policy focus from HIV prevention-only strategies to 
prevention plus treatment. 
Methods 
Criteria for selecting studies for this review: 
The principle investigator performs a systematic search of the literature to 
select studies, with the inclusion considerations being study design, geographic 
location, study participant characteristics, type of intervention, and health 
outcomes. 
Study Designs: Study designs must be randomized controlled trials 
(RCT), prospective cohort studies, retrospective cohort studies, or case series 
published between January 1996 and April2004. The study must enroll at a 
minimum twenty participants. Although randomized controlled interventions are 
ideal to determine effectiveness, few published studies likely exist that use an 
experimental RCT study design, owing to ethical considerations. 
Geographic Location: Studies must be conducted in Haiti or a country of 
sub-Saharan Africa (Botswana, Namibia, Mozambique, Zimbabwe, Zambia, 
Angola, Malawi, Tanzania, Congo, Zaire, Kenya, Gabon, Guinea, Cameroon, 
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Uganda, Nigeria, Benin, Togo, Ghana, Cote d'Ivoire, Liberia, Sierra Leone, 
Senegal, Mali, or South Africa). 
Study Participants: Participants must be adults (defined as 13 years or 
older, as used in the CDC classification, which includes adolescents28) who are 
infected with HIV, and may or may not have an AIDS diagnosis or AIDS-related 
symptomatology. Studies with both male and female participants will be 
considered, though studies that include pregnant female participants treated with 
ART only to prevent transmission ofHN from mother to infant will be excluded. 
Criteria for HN infection and AIDS include those specified by the CDC (1993-
revisedi8or by WHO classification (Clinical Stage 4)29 
Intervention: Studies must provide an intervention of ART, either a single 
dmg or multi-dmg regimen, to HN-positive, non-pregnant adults for the 
treatment ofHIV/AIDS. The intervention can be either directly observed therapy 
(DOT) or non-DOT. 
Health Outcomes: Principal health outcomes include probability of 
survival; the proportion of patients achieving an undetectable HN -ribonucleic 
acid (RNA) level (viral load), e.g. viral load less than 50 viral copies/ml; mean 
change in CD4+ cell count relative to baseline; and change in HIV-RNA levels 
relative to baseline. Secondary health-related outcomes include clinical outcomes 
such as adverse dmg events, adherence, and any quality oflife indicators the 
studies report. The review will report adverse advents as either minor or major. 
Major events will be those severe enough to require change or discontinuation of 
treatment. 
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Search strategy for identification of studies 
To identifY relevant articles, the principal investigator searched the 
MEDLINE database via PUBMED, restricting the search to published articles 
from January 1996 through April2004. The MEDLINE search used the Medical 
Subject Headings (MeSH) '"HIV' AND 'DEVELOPING COUNTRIES'" Limits 
were set for "adult" and "human." This yielded very few ART programs, and the 
investigator consulted a reference librarian at the Health Sciences Library at The 
University of North Carolina at Chapel Hill. 
The revised search utilized the following search terms: 
"ANTIRETROVIRAL AND (AFRICA OR BOTSWANA OR NAMIBIA OR 
MOZAMBIQUE OR ZIMBABWE OR ZAMBIA OR ANGOLA OR MALA WI 
OR TANZANIA OR CONGO OR ZAIRE OR KENYA OR GABON OR 
GUINEA OR CAMEROON OR UGANDA OR NIGERIA OR BENIN OR 
TOGO OR GHANA OR COTE D'IVOIRE OR LIBERIA OR SIERRA LEONE 
OR SENEGAL OR MALI OR HAITI)" The investigator set the following limits: 
"All Adult, Publication Date from 1996 to 2004, Human." The revised search 
yielded 127 articles on April 8, 2004. The investigator conducted the same search 
again on April19, 2004, which yielded an additional two articles. 
In addition to the PUBMED search above, the principal investigator 
performed a search of Cochrane Data Base of Systematic Reviews via OVID 
using the search term "antiretroviral," and a search using CINAHL (via 
EBSCOHost) with the keywords "HIV AND developing countries." These 
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searches yielded no additional articles. A search of the NIH, CDC, and UN AIDS 
websites yielded no additional studies for consideration. 
Lastly, the investigator's consultation of infectious disease experts at the 
University of North Carolina at Chapel Hill identified an unpublished manuscript 
in Malawi, Africa for consideration. 
Results 
Data abstraction 
The principal investigator examined titles and abstracts of the 127 articles 
identified by the PUBMED search and the additional one unpublished manuscript 
from Malawi and assessed them for the selection criteria specified above. Of the 
127 articles identified from the search, only 27 articles initially appeared to meet 
the inclusion criteria, for which the investigator reviewed the full texts. Ten of 
these articles met the selection criteria and were included in the analysis. Two of 
these articles addressed the same antiretroviral program, so a total of nine ART 
programs in Africa and Haiti were identified-eight in Africa and one in Haiti. 
The most common reasons for exclusion of articles included the following: the 
article addressed only antiretroviral use for the prevention of maternal-fetal 
transmission; the article evaluated only non-retroviral care ofHIV/AIDS patients; 
or the article represented the authors' expert opinion with no evidence-based 
findings. 
Once the principal investigator selected articles for inclusion in the 
review, he abstracted relevant information from each article and placed it into 
evidence tables (Tables 1 and 2). Descriptions of each study are presented in 
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Table l, with the variables being author, year, study location, study dates, study 
design, study setting, type of ART intervention, delivery method of ART, 
intervention duration, whether or not patients have to pay for study drugs, number 
in sample, percent lost to follow-up, and whether or not intention to treat analysis 
was carried out. Table 2 presents baseline characteristics and outcomes that were 
abstracted from the selected studies. Baseline data extracted include whether or 
not participants had taken antiretroviral medications at some time prior to the 
study, CD4 count, and viral load. Outcomes that were measured post-intervention 
included percent of patients with undetectable viral load, CD4 cell count change, 
viral load change, probability of survival, adherence data, and any adverse drug 
events. 
The primary investigator combined outcome data wherever possible to 
calculate a weighted mean value, with the denominator consisting only of those 
participants for whom studies reported values. 
Methodological description of selected studies 
All ten of the selected studies employed non-randomized, and in most 
cases uncontrolled, drug trials to determine effectiveness of ART in Africa and 
Haiti. Kebba, et al. conducted a retrospective cohort study in Uganda comparing 
the effectiveness of three different ART regimens. This Uganda study did not 
randomize patients into treatment groups and did not include a placebo control 
group for comparison. The remaining studies consisted of prospective and 
retrospective case series designs in which the investigators or programs 
administered ART to participants and followed them to observe what outcomes 
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occurred without the use of control groups. With no comparison groups in these 
descriptive studies, no basis exists to conclude that outcomes represent an 
improvement over the natural course of the disease or that outcomes result from 
the ART intervention itself. These studies describe the frequency of occurrence 
of health outcomes associated with the ART intervention, but their study design 
precludes them from providing definitive evidence for the effectiveness or 
ineffectiveness of ART in Africa and Haiti. They describe initial attempts to treat 
HIV positive individuals in these resource-poor regions and may generate 
hypotheses to be later tested in randomized trials and ideas to be incorporated in 
the planning and execution of future programs. 
The studies evaluated programs in the Central Plateau of Haiti (Farmer, et. 
aT/· 8 and in five large sub-Saharan African cities: two studies in Abidjan, Cote 
d'Ivoire (Djomand, et. al and Seyler, et al.);30' 31 two in Kampala, Uganda 
(Weidle, et. al. and Kebba, et al.);32• 33 two in Dakar, Senegal (Landman, et al. and 
Laurent, et al.);34• 35 one study in Capetown, South Africa (Orrell, et al.i6; and 
one in Lilongwe, Malawi (Hosseinipour, et al.). 37 Each of the sub-Saharan 
African studies took place in tertiary care centers, outpatient clinics, and military 
hospitals, all within or near large cities. These medical centers represent the best 
medical care available in their respective countries, which contrasts greatly with 
the level of care available in more mral areas where health care infrastmcture is 
likely much more limited or non-existent. This confines the generalizability of 
these study results to ART programs in larger cities with relatively well-
developed health care infrastmctures. The program described by Farmer, et al. in 
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Haiti, however, differs from the African studies, as it operates from a small clinic 
in a poor, mral setting, so that its results might be more widely generalizeable to 
poorer areas with fewer resources. 
The amount of money patients paid for ART differed greatly among 
studies. The South African and Haitian studies and the study by Seyler, et al. in 
Cote d'Ivoire completely subsidized ART medications, and the programs 
evaluated by Djomand, et al. in Cote d'Ivoire and by Laurent, et al., in Senegal 
heavily subsidized ART. The remaining studies either provided no ART subsidy 
or did not specify the amount patients paid. Those studies that did not provide 
subsidies likely selected wealthier patients for inclusion, which may bias results 
toward better outcomes if higher socioeconomic status acts as a confounder to 
contribute to improved outcomes. The results of the programs that provided ART 
free of charge are more widely generalizeable, as most HN-infected patients in 
Africa and Haiti are poor and unable to afford antiretroviral medications without 
financial assistance. 
Description of study participants 
Both Ugandan studies and Landman, et al. in Senegal enrolled only 
patients infected with HIV-1, which limits the generalizeability of their results, as 
HN -2 infection is not uncommon in Africa. Laurent, et al. in Senegal enrolled 
fifty patients with HN-1 and only three patients co-infected with HN-1 and HN-
2. The other studies did not specify HN type. Djomand, et al. in Cote d'Ivoire; 
Kebba, et al. in Uganda; and both the Senegalese studies included only patients 
with no prior history of ART use, which renders their results readily generalizable 
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to only ART-naive patients. Weidle, et al. in Uganda and Hosseinipour, et al. in 
Malawi included both ART-naYve and experienced patients, but did not 
breakdown outcomes by ART status. The Haitian and other Cote d'Ivoire study 
do not specify participant ART status. 
Baseline clinical and immunovirological data show that the majority of the 
participants in these studies had advanced HIV -disease. CD4+ cell counts were 
below 200 in a majority of patients in all studies, though the Haitian study did not 
specify baseline CD4+ count. Mean baseline viral load exceeded 200,000 
copies/ml in all studies that report values. Seyler, et al. in Cote d'Ivoire; the 
Senegalese studies; and Hosseinipour, et al. in Malawi emolled a majority of 
patients with WHO stage 3 or 4 disease or CDC stage B or C disease, late clinical 
stages ofHIV infection. The severity ofHIV disease contributes to the 
generalizeability of these studies to other populations in Haiti and sub-Saharan 
Africa where HIV testing and counseling programs are sparse, and HIV infection 
is therefore commonly diagnosed at a relatively later stage than in more 
developed countries. 
Description of stndy interventions 
Study interventions included provision of a variety of antiretroviral agents, 
alone or in combination, to include the following drug classes: nucleoside reverse 
transcriptase inhibitors (NRTI), non-nucleotide reverse transcriptase inhibitors 
(NNRTI), and protease inhibitors (PI). One category of drug combination 
employs the use of two NRTis (2NRTI). Highly active antiretroviral therapy, 
another retroviral combination, was defined as the use of a NR TI with a NNRTI, 
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PI, or abacavir. All nine programs provided HAART as an intervention. The 
Cote d'Ivoire and Uganda studies also provided 2NRTI to participants. The 
Haitian program delivered DOT-HAART via community health workers. The 
Senegalese program evaluated by Landman, eta!. delivered a non-DOT one pill 
per day HAART regimen. The other studies did not specify whether or not ART 
was directly observed. A central pharmacy dispensed antiretroviral medications 
in the Cote d'Ivoire studies; in Landman, eta!. in Senegal; and in Orrell, eta!. in 
South Africa. This allowed for tighter control over medication dispensation. 
Duration of ART varied from a median of ninety-four and 152 days (HAART and 
2NRTI, respectively) in Weidle, eta!. in Uganda to 546 days (19.5 months) in the 
Laurent, eta!. Senegalese study. 
Orrell, et. a!. in South Africa reported eighty-seven percent adherence 
without DOT, and Landman reported ninety-five percent adherence in Senegal 
with once a day dosing without DOT. The study by Farmer, et. a!., the only study 
using DOT, does not report adherence, so no comparison can be made between 
DOT and non-DOT ART programs. Randomized control trials should be 
conducted, using HAART as the standard of care, to compare DOT programs 
versus non-DOT programs. 
Changes in health outcomes 
Despite initially high drug costs, a small pilot HN/AIDS project in a poor 
rural community in Haiti provides directly observed therapy (DOT) with HAART 
to sixty patients with advanced HN disease. 1' 8 The project serves patients in the 
poorest part of the poorest country in Western hemisphere and was built on an 
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existing TB-control infrastructure. The project initially began providing 
zidovudine to HN infected pregnant women, which led to dramatic decline of 
vertical transmission ofHN to infants. It expanded in 1997 to provide post-
exposure prophylaxis with three-drug regimen to victims of rape or professional 
injury. In 1998 it began to provide HAART to patients with long-standing HN 
infection. 1' 8 
The Haitian pilot DOT-HAART program, modeled on successful TB 
control efforts, provides each HN patient with a community health worker who 
observes ingestion of medications, responds to patient/family concerns, and offers 
moral support. Support includes help with children's school fees; free, 
uninterrupted access to medications; continuity of care; and monthly meetings. 
The initial cohort of sixty patients experienced dramatic responses to HAART. 
HAART-treated patients were far less likely to enter the hospital than were non-
treated patients, and the HN viral load dropped to undetectable levels in most 
patients. Many of these patients returned to work and to caring for their 
families. 1' 8 
All studies that report values show an adherence, reduction in plasma viral 
load, and increases in plasma CD4+ cell count comparable to those of studies 
conducted in developed countries using similar ART regimens. Overall, 
participants in ART programs in Africa and Haiti took eighty-two percent of 
medications and experienced a weighted mean loglO viral load reduction of 1.83 
after approximately one year of treatment. Sixty-five percent of all participants 
achieved an undetectable plasma viral load, the definition of which varied with 
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the sensitivity of the laboratory test from less than fifty RNA copies/ml to less 
than 400 copies/mi. Plasma CD4+ cell count increased by a weighted mean of 
123 x 106 cells/L. Adherence and viral load suppression in these sub-Saharan 
African and Haitian studies compare favorably to adherence and virologic 
outcomes in developed countries where studies report an adherence of seventy 
percent and viral load suppression to undetectable levels in fifty percent of 
patients on similar ART regimens.34• 36• 38-45 Overall survival in the Haitian and 
African studies was eighty-percent. 
Adherence was generally higher among programs that provided ART free 
of charge, though this trend may or may not be statistically significant. Further 
studies should be conducted to determine those factors that contribute to 
adherence in non-DOT sub-Saharan African programs. Loss to follow-up also 
reflects this trend. Among programs that provided ART subsidies, loss to follow-
up ranged from zero percent to 1.7 %. Loss to follow-up ranged from twenty-four 
to forty-two percent in programs that provided no subsidy. Most studies reported 
unscheduled treatment interruption, most often owing to pharmacy stock 
shortages and lack of personal resources. 
The average incidence of medication-related adverse events was ten 
percent, and most of these events were minor, such as gastric discomfort, not 
necessitating a discontinuation of therapy. No study reported any dmg-related 
deaths. 
Discussion 
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Results from these studies show clinical, virological, and immunological 
responses to antiretroviral therapy in sub-Saharan Africa and Haiti that compare 
favorably with those same responses in industrialized countries, despite 
differences in the HIV -1 subtype distribution in Africa and the fact that many of 
the sub-Sahara African studies enrolled a majority of patients with advanced 
disease. These studies suggest that ART interventions can be implemented in 
sub-Saharan Africa and Haiti, and can demonstrate improvements in surrogate 
markers for health outcomes, such as viral load, CD4 counts, and adherence. 
Financial constraint emerged as the leading cause for non-adherence. 30 
Most sh1dies reported unscheduled treatment interruption, most often owing to 
dismption in the provider's dmg supply (pharmacy stock shortages) or to lack of 
personal resources. Programs that provided medications, monitoring, and other 
care free of charge to patients achieved much greater rates of adherence. 
Adherence likely contributes to decreased viral resistance and has been shown to 
correlate with better virologic suppression and immune recovery and with 
decreased HIV -related morbidity and mortality. 36 41 -47 . In those studies in which 
antiretroviral supply was assured, viral resistance rarely emerged. HAART was 
well-tolerated, at least in the short-term, in these studies. 
Many individuals in sub-Saharan Africa who can afford ART medications 
already use them, sometimes sporadically, as individual resources allow. As dmg 
prices continue to fall, more and more Africans are likely to use antiretrovirals, 
whether or not organized programs exist to ensure their proper prescription and 
use. Failure to establish organized well-maintained ART programs will likely 
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result in indiscriminate antiretroviral use that contributes to dmg toxicity, sub-
optimal clinical results, and the emergence of antiretroviral-resistant viral strains. 
Secondary benefits from ART 
Improvement of health care infrastructure in Africa and Haiti to facilitate 
the provision of ART will likely contribute to better health outcomes in other 
diseases, as well. The lack of infrastructure argument, however, should not be a 
deterrent to developing and implementing ART interventions. Instead, further 
research should be undertaken to evaluate these interventions for their 
effectiveness in settings oflimited health infrastruch1re, and the optimal way of 
doing so would be through randomized controlled trials. 
Perhaps most importantly, providing HN treatment--a biomedical attempt 
to ameliorate a social as well as biological problem-may have even more 
profound positive secondary and tertiary psychological and societal effects. 
Providing treatment to the millions most in need not only fills an immediate need; 
it evens the playing field, reduces inequality, and brings into the fold those on the 
fringes of society, lifting them from the lowest rungs of the societal ladder to give 
them hope and a future. 
HN/AIDS decreases resistance to tuberculosis (TB), and the global spread 
ofHN threatens TB control efforts worldwide. HN/AIDS dramatically 
increased the incidence ofTB in sub-Saharan Africa, where up to sixty percent of 
TB patients are co-infected with HIV, and each year 200,000 TB deaths are 
attributable to HN co-infection. HN now threatens control ofTB in Asia, 
Eastern Europe, and Latin America. Treating HN with ART could therefore 
19 
secondarily aid TB control in developing countries. In addition, TB programs 
provide an important entry point for the treatment ofHIV/AIDS, as was the case 
in the program evaluated in Haiti. 
Factors contributing to program success 
Several factors contribute to the success of the ART programs evaluated 
by the studies in this review. Perhaps most important are the free provision of an 
uninterrupted supply of ART medications and the availability of regular medical 
care. If ART is available, but not made affordable for the impoverished 
individuals who need it, or ifHIV-infected individuals have no access to regular 
medical care, patients will not use the available medications, or may use them 
improperly or sporadically, possibly leading to resistant viral strains. Falling drug 
prices make the free provision of ART much more feasible. Because the presence 
of HIV infection is readily and well defined through HIV testing, patients are 
unlikely to ovemse free HIV treatment services. 
Strong public control and support are also required for successful ART 
expansion. 17 Strict control of ART medications and close follow-up of patients 
will prevent illegal and inappropriate trade in the informal market that may lead to 
resistance. 17• 27 Guidelines should be in place before administering ART to 
prevent dmg resistance, and a program must train health care workers how to 
administer antiretroviral medications effectively. Using existing TB programs as 
delivery mechanisms for ART, as in the ART program in Haiti, may facilitate the 
establishment or expansion of ART programs. 
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Follow-up and social support by pharmacists, physicians, other medical 
personnel, support groups, and social or community workers may also contribute 
to program effectiveness. In Haiti, Haitian patients value the moral support 
provided to their families, and may perceive those who use this tactful approach 
as better health care workers. The fact that caring community members 
administered the intervention, as opposed to culturally insensitive physicians or 
nurses, might partly explain the success of the program. It is possible that Haitian 
communities value their autonomy and might resist taking orders from an outside 
doctor, so that this community-led approach is more likely to be accepted and to 
produce better health outcomes than would be a rigid clinic-based system such as 
we have in the U.S. This is one example of an AIDS treatment program 
providing ART in an extremely impoverished area despite the lack of a developed 
health infrastructure. 
A once a day regimen, such as that in Senegal,48 allows patient 
confidentiality to be more easily maintained, as the patient can take the 
medication at bedtime without the knowledge of other family members. Ease of 
administration and maintenance of confidentiality will likely increase adherence 
to ART. Adherence in the Senegalese one pill per day program was enhanced by 
the regimen's simplicity, tolerability, and uninterrupted supply. 
A thorough knowledge of the culture and health care system of the region, 
country, or community in which the program will operate will also greatly 
contribute a program's success. Programs in different regions may look different, 
as they should be designed and adapted to use the existing strengths of the 
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national or local healthcare system and other attributes of the region to include 
local culture and leadership. A detailed, theoretically well-conceived program 
designed to deliver efficacious medications may prove clinically irrelevant and 
ineffective on the ground owing to simple yet grave oversights, even when great 
effort is made to incorporate all available information into the planning process. 
Therefore a program plan must be flexible and amenable to change once the 
program is put into practice. 
The presence of the four Cs-- concern, commitment, competence, and 
continuity-- is essential for program success.49 These may come from 
govermnent, national health officials, local leaders, or program leaders. A 
successful program conducted in a country such as Uganda where the four Cs are 
present will unlikely be as successful if carried out in Botswana or South Africa 
where the four Cs may be absent and relatively little or no attention been given to 
HIV as a national health care priority. The Haiti study is important in that it 
shows an HN program operating in a country where the four Cs are absent. A 
program designer should first find out to what degree the four Cs are present in a 
country or region before designing and implementing an HN program or any 
program. If concern, commitment, competence, or continuity is lacking, an ART 
program leader may be able to provide the missing component or components, but 
he or she will almost certainly meet resistance to create a new environment in 
which a program will flourish. Program leaders in Haiti appear to have stepped in 
to fill a four Cs gap in a small, poor region in Haiti. Many such leaders will be 
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necessary in a country devoid of leadership, and program designers should be 
aware of this before establishing any program. 
For the establishment and maintenance of a program designed to treat 
large numbers of people, a strong national government that recognizes a problem 
and commits itself to solving it is indispensable. A few countries in sub-Saharan 
Africa, such as Uganda, may provide this favorable environment, while many 
may not. A small, isolated program, such as that in Haiti, will experience 
problems with its prevention efforts, as it cannot influence what goes on in larger 
cities where many rural inhabitants go to work. 8• 50 Local prevention efforts do 
little to prevent people from going to the city and bringing HIV back home. 
Barriers to overcome 
Even with recent price decreases, the price of antiretroviral medications is 
still a major issue for Haiti and the countries of sub-Saharan Africa with limited 
health care budgets. Countries must create supply and distribution networks for 
antiretroviral and other medications and laboratory materials to facilitate 
adherence. The diagnosis and treatment of opportunistic infections is deficient in 
many parts of Africa and Haiti. Many patients in these studies came for treatment 
late in the course of their disease. Frequent use ofless effective lower cost 
2NRTI regimens for patients with advanced stages of disease may compromise 
clinical response to ART. The marginal cost of a third drug required for HAART 
was unaffordable for many, even for the relatively wealthy patients in these 
studies. 
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The high costs of laboratory monitoring also presents a potential barrier to 
ART programs. As with ART, the price oflaboratory testing is dropping. Former 
President Bill Clinton recently announced a deal he negotiated with five 
companies that manufacture laboratory tests. One of the companies, Becton, 
Dickinson & Co., reduced the cost of its CD4+ cell count from $10 to $3. 19 
Woefully inadequate healthcare infrastructure in Haiti and sub-Saharan 
Africa is a reality. Most of the studies reviewed in this paper were conducted in 
the best medical centers of the respective participating countries. The existing 
infrastructure in the surrounding areas may not support the expansion of the ART 
programs. The Haiti program operates in one of the poorest regions of Haiti. It 
builds, however, on an already successful non-government organization (NGO) 
TB treatment program in place for years before it began providing ART to HIV 
patients. Haiti and the countries in sub-Saharan Africa likely need to expand and 
improve their healthcare infrastructure to facilitate the provision ART or any 
other therapy, though the existing infrastructure supports TB therapy to some 
extent. 
Perhaps the most formidable barriers to the provision of ART in Haiti and 
sub-Saharan Africa are the absence of"the four C's:" concern, commitment, 
competence, and continuity. Until recently, many sub-Saharan African leaders 
denied or ignored HIV as a major problem in their respective countries. Until 
leaders acknowledge HIV/AIDS as a problem, they cannot begin to develop 
solutions. 
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Current discourse at international forums and the formation of 
organizations and initiatives such as UNAIDS, the Global Fund, and the 3X5 
Initiative reflect an increasing concern for the millions of HN I AIDS patients in 
the poorest areas of the world and a commitment to reduce the inequalities of 
ART availability. Remaining to be seen, however, is if the global community is 
competent to treat HN I AIDS in poor areas ofthe world and if it can provide the 
continuity to ensure the success of providing ART to those most in need. 
Antiretroviral therapy only a partial fix 
Uncontrolled spread of infection marks societies with woefully deficient 
resources and minimal exposure to disease prevention education, though a 
cotmtry' s HN epidemic could start anywhere for reasons that have nothing to do 
with poverty. The disease was initially spread among homosexual men in the 
U.S., and through the jet-set in Brazil, but no matter how HN enters a country, 
HIV infection travels downhill along a common pathway of least resistance to 
settle among the most marginalized51 HNIAIDS tracks along social fault-lines 
to find the poor. Poverty and inequality are the risk factors most strongly 
associated with HIV infection and AIDS-related mortality. 8• 52-54 
HIV I AIDS is a dye that stains the world for the presence of poverty and 
inequality. Where there is HN, there is poverty and inequality. The 
entrenchment and uncontrolled spread ofHN I AIDS in impoverished areas is a 
symptom, a surrogate marker for deeper societal and global problems that existed 
long before the HIV I AIDS pandemic. The pandemic merely paints the earth and 
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allows us to epidemiologically map the location of these more fundamental 
problems. 
Successful HN treatment, or even the development of an effective 
vaccine, solves only the surface problem. Malaria, TB, and other diseases still 
stain the impoverished and the marginalized. Other diseases are likely to emerge, 
as well. Further technological advances will have minimal impact if national and 
international leaders fail to address the deeper societal issues affecting disease 
management. 
Future Research 
Most studies examine only ART-nai:ve patients infected with HN-1. 
Future research should concentrate on HN-2 infected individuals and on ART-
experienced patients, as well, as these patients represent a significant portion of 
the populations of sub-Saharan Africa. A small, limited study by Adje-Toure, et 
al. in Cote d'Ivoire (not included in this review) ofHN-2 patients receiving ART 
showed nelfinavir-containing ART regimens may have little or no 
immunovirologic effect on patients infected with HN-2.55 Further studies should 
identify those ART regimens effective against HN -2. 
The short duration of these studies may fail to demonstrate possible 
antiretroviral drug intolerance and the development of antiretroviral resistant HN 
strains. Future longer-term studies may reveal dmg intolerance to be an 
adherence issue, as it already is in industrialized nations30 Therapeutic cohort 
studies should also study long-term survival, morbidity, immunovirological 
response, and drug resistance in sub-Saharan Africa and Haiti. 
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Farmer, et. al. advocate the use of DOT for the provision of antiretroviral 
drugs in resource-poor settings8, though evidence for the superiority of DOT 
versus non-DOT treatment is limited. 56 For example, Orrell, et. al. in South 
Africa reported eighty-seven percent adherence without DOT. One might argue 
that DOT might have resulted in even greater adherence. Randomized control 
trials should be conducted, using HAART as the standard of care, to compare 
DOT programs versus non-DOT programs. Randomized trials should also 
compare programs that provide different mixtures of social and financial support 
to determine which supplementary interventions prove most effective and 
feasible. Differences in the way a program is designed and administered may 
make larger differences in treatment outcomes than do choices of specific 
antiretroviral combinations, though research should continue to sort out which 
drug combinations provide the greatest benefit, given the prevalence ofHIV-2 
and many HIV -1 subtypes in sub-Saharan Africa not found in other areas of the 
world. 
Limitations of this systematic review 
Ideally two other readers would independently review the titles and 
abstracts of the 128 articles identified by the literature search. Those articles the 
independent reviewers agreed did not meet eligibility criteria would be excluded. 
If the initial reviewers disagreed, the investigators would carry the full text 
articles to the next review stage in which the investigators would review the full 
text articles and make a final decision about inclusion or exclusion by consensus. 
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The primary investigator alone selected articles for inclusion in the review 
and abstracted relevant information from each article and placed it into evidence 
tables. Ideally, two independent investigators would perform this information 
abstraction. One reviewer would have abstracted the relevant information and 
placed it into the evidence tables, and a second investigator would then check 
these tables and note any discrepancies, which would then be resolved by 
consensus. Owing to the limited resources available for the production of this 
systematic review, the primary investigator carried out the above review process. 
Limitations of this review also include the investigator's limited 
experience in Africa and Haiti and relative unfamiliarity with the history, politics, 
economics, health care systems, and culture of Haiti and sub-Saharan African 
countries. 
Conclusion 
Antiretroviral therapy programs in sub-Saharan Africa and Haiti achieved 
similar health outcomes as did treatment programs in wealthier Western countries. 
These studies suggest that ART works in African patients. The major issue is 
how to expand existing programs and establish new ones to get the medications to 
those in need. Free access to uninterrupted antiretroviral medications and regular 
access to a primary care provider are essential to success of any ART program in 
these resource-poor areas. International and national concern, commitment, 
competence, and continuity on the behalf of political, health, and community 
leaders will greatly increase the likelihood of success ofthe difficult undertaking 
to provide ART millions in need of it. 
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"In war it is the things which are thought impossible which most often 
succeed, when they are well conducted. "20 
--Eighteenth century general 
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Table 1. Study Description 
Author, year, 
location 
Djomand, et. a/. 2003 
Abidjan, Cote d'Ivoire 
Seyler, et. a/. 2003 
Abidjan, Cote d'lvoire 
Weidle, et. a/. 2002 
Kampala, Uganda 
Kebba, et. a/. 2002 
Kampala, Uganda 
Landman, et. a/. 2003 
Dakar, Senegal 
Laurent, et. al. 2003 
Dakar, Senegal 
Oneil, et. a/., 2003 
Capetown, S. Africa 
Hosseinipour, et. al., 
2004 
Lilongwe, Malawi 
Farmer, et. al., 2001 
Central Plateau, Haiti 
NS =not specified 
ITT = intent to treat 
Study Design 
Retrospective 
case series 
Prospective 
case senes 
Case series 
Retrospective 
cohort 
Prospective 
case series 
Prospective 
case senes 
Prospective 
case series 
Retrospective 
case series 
Case series 
Study Setting 
Tertiary care 
Outpatient clinics 
Clinical research 
Center 
3 centers in/near 
Kampala 
Rease arch 
center 
Two hospitals 
in Dakar 
NS 
University HIV 
HIV clinics 
Lilongwe Central 
Hospital 
Rural clinic 
ART Delivery 
Intervention method 
(n) 
HAART(276) Central 
2NRTI (204) pharmacy 
HAART(90) Central 
2NRTI ()I) pharmacy 
HAART (29) NS 
2NRTI (74) 
HAART (16) NS 
2NRTI (9) 
HAART (40) Non-DOT 
One pill/ day 
Central 
pharmacy 
HAART (58) NS 
HAART(244) Non-DOT 
2NRTI (45 Central 
phannacy 
HAART(625) NS 
HAART(60) DOT-HAART 
by conununity 
health worker 
Intervention Free or Patient n Loss to ITT 
Duration Pays for Drugs Follow-up 
%subsidy) 
NS 50-95% subsidy 480 N/A NS 
Median (IQR) 90% subsidy; then 101 0% NS 
17 months (13-30) 100% for poorest 
after Jan 2001 
Median (IQR) No subsidy 103 24% Yes 
HAART 94d (33-278) 
2NRTI152d (28-385) 
HAART: NS 25 N/A NS 
EFV 30.6 +/-5.9 wks 
IDV 30.8 +/-4.7 wks 
2NRTI: 30 +/-9.7wks 
15 months NS 40 0% 6mo. Yes 
2.5% 14mo. 
Median (IQR) Patients paid US$34 58 1.70% Yes 
19.5 mo (10.7-23.9) Rest subsidized 
83.8% >48 wks. 100% subsidy 289 0% NS 
16.2% <48 wks 
Median (IQR) No subsidy 625 42% NS 
ART: 201 d (49-337) 
NS 100% subsidy 60 NS NS 
Table 2. Baseline Characteristics and Outcomes 
Author, year, n 
location 
Djomand, 480 
et. al., 2003 
Cote d'Ivoire 
Seyler, 101 
et. a!., 2003 
Cote d'Ivoire 
Weidle, 103 
et. al., 2002 
Uganda 
Kebba, 25 
et. al., 2002 
Uganda 
Landman,. 40 
et. al. , 2003 
Senegal 
Laurent, et al. 58 
2003, Senegal 
Orrell, 289 
et. al., 2003 
S. Africa 
Hosseinipour, 625 
2004, Malawi 
Farmer, et. a!. 60 
2001, Haiti 
Total (n) 1781 
NS= not specified 
EFV = efavirens 
lDV = indinavir 
Baseline 
ART status 
ART-naYve 
100% 
NS 
HAART: 
57% naive 
2NRTI: 
65% naive 
ART-naYve 
100% 
ART-naYve 
100% 
ART-naYve 
100% 
ART-naYve 
100% 
47% naive 
NS 
37% naive 
Base CD4 Baseline Viral 
(xlO"IL) Load (copies/mL) 
<200 n 331 <10,000 (33) 
>200 n~J27 10-99,000 (64) 
missing=22 >100,000 (324) 
<50 n~21 Median log10 (IQR 
>50 n~73 5.3 (4.8-5.8) 
missing=? 
Median HAART 233,523 
HAART78 2NRTI 187,469 
2NRTI 55 
HAART: HAART: 
EFV med 19 EFV 565 
IDV med 16 IDV 219 
2NRTI: 200 2NRTI: 320 
Mean 164 Mean log!O 
5.4 (+/- 0.4) 
Median 109 Median (IQR) 
108 (28-217) 
Mean 256 Mean logiO 
5.53 
Median 70 NS 
NS NS 
0/o with undetect. Mean loglO CD4 chg Probability of Adherence Adverse 
Viral Load (VL) change VL (xlO"/L) Survival Drug Events 
50% at I yr P.9at I yr. t>IOO I yr 0.84 lyr NS 69 events 
( <200copies/ml) severity NS 
51% at I yr NS tJI5lyr By base CD4 NS Severe: 10 
>50: 0.96 lyr 
<50: 0.80 lyr 
>50: 0.94 18mo 
<50: 0.76 18mo 
HAART: 39% lyr At I year: HAART: 0.74 I yr 6 mo. 0.77 NS 
2NRTI: 24% 1yr HAART: tJ.5 t75 1 yr I yr. 0.67 
( <400 copies/ml ) 2NRTI: tQ.3 2NRTI: 
t42 !yr. 
HAART: NS NS NS NS Minor: 2 
EFV 71% at 31wk 
IDV 80% at 31 wk 
2NRTI: 12% 31wk 
( <400 copies/ml) 
70% at 1 year P.4 at 15 mo tJ99 NS 95% Minor 2 
77% at 15 months 
(<50 copies/ml) 
NS t2.3 at 12 mo tJ47 !yr. 85% 12 mo >80% adh. Severe: 8 
!2.8 at 18 mo tJ 79 1.5yr 82.3% 18 mo in88% Minor: 39 
I-IAART: 71% NS NS NS Med 94% Major: 5 
Dual tx: 41% Mean 87% 
( <400 copies/ml) 
NS NS tJI5 6mo. NS NS Major: 25 
[89, 141] 
86% (time NS) NS NS NS NS NS 
65%* (935) ! 1.83* (681) 123 (1244 0.82* (735) 83%*(432) 10% 
*calculated from data closest to one year, weighted for number of participants with values. 
